



Orphan Drug status for Intercell's Japanese Encephalitis Vaccine granted by the European Commission

Vienna (Austria), January 30, 2006 – Intercell AG (VSE, "ICLL") announced today that the company's Japanese Encephalitis vaccine, currently in advanced Phase III trials, has been granted orphan drug status by the European Commission.

The European Commission has followed a recommendation of a designated working party at EMEA (European Medicines Agency), which has reviewed the program from Intercell.

The EMEA's orphan medicinal product designations are based on various criteria that include the seriousness and incidence of the condition and the availability of other effective therapies.

The orphan drug designation leads to several important advantages within the development and especially the marketing of Intercell's lead product:

- » With the licensure of Intercell's Japanese Encephalitis vaccine, the company will receive 10-year sole exclusive market rights for its product within the EU25 countries including Norway and Iceland.
- » The orphan drug designation for Intercell's Japanese Encephalitis vaccine also includes fee reduction and waivers during the pre- and post-approval phases of the product and special participation in EU funded projects and protocol assistance for additional trials, as for instance pediatric trials.

"We are convinced that our modern cell culture based vaccine will increase the market potential for vaccination of travelers against the Japanese Encephalitis Virus. The orphan drug status allows us to generate a maximum commercial benefit for our product in the EU", states Gerd Zettlmeissl, CEO of Intercell.

About Intercell's JE vaccine

Intercell's novel Japanese Encephalitis vaccine is a purified, inactivated vaccine for active immunization of adults against the Japanese Encephalitis virus and has successfully concluded Phase II clinical trials.

In a Phase II head-to-head comparison with JE-VAX®, Intercell's vaccine was shown to be:

- » Less reactogenic - both in frequency and intensity
- » More potent - higher antibody levels at all doses studied one month after the immunizations; this vaccine also showed high seroconversion rates one month after a single dose
- » More convenient - 2 doses versus 3 doses and liquid versus freeze-dried format
- » More persistent – higher persistence of antibodies two years after primary immunization



The global Phase III clinical trials consist of immunogenicity studies in about 860 individuals as well as large safety trials in about 4000 subjects.

About Intercell

Intercell AG is a fast growing biotechnology company focusing on the design and development of novel vaccines for prevention and treatment of diseases with substantial unaddressed medical need. The Company's unique position is based on the combination of antigens and immunizers (adjuvants) derived from its proprietary technology platforms and its in-house GMP manufacturing facilities. Intercell's technology has been endorsed by collaborative agreements with a number of global pharmaceutical companies, including sanofi pasteur, Merck&Co., Inc., SciGen Ltd. and the Statens Serum Institut. The Company has a broad development pipeline with a vaccine for Japanese Encephalitis in Phase III, a vaccine for Hepatitis C in Phase II, a partnered Tuberculosis vaccine as well as a partnered *S. aureus* vaccine in Phase I and five products focused on infectious diseases in pre-clinical development. Intercell is listed on the Vienna stock exchange under the symbol "ICLL". For more information please visit: www.intercell.com

Contact Intercell AG:

Intercell AG

Katharina Wieser

Head of Corporate Communication

Campus Vienna Biocenter 2

A-1030 Vienna

P: +43-1-20620-303

Mail to: kwieser@intercell.com

This communication expressly or implicitly contains certain forward-looking statements concerning Intercell AG and its business. Such statements involve certain known and unknown risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of Intercell AG to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Intercell AG is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.